The comparison of optimized pharmacodynamic dosing strategy for meropenem using Monte Carlo simulation

Japanese Journal of Antibiotics

Volumn 58, Issue 2, 2005, Pages 159-167

  Mikamo, Hiroshige ^a   Totsuka, Kyoichi ^b  

^a GIFU UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MEROPENEM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; DRUG DOSE REGIMEN; DRUG SENSITIVITY; DRUG SURVEILLANCE PROGRAM; ESCHERICHIA COLI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA;

ADULT; ESCHERICHIA COLI; HUMANS; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; THIENAMYCINS;

EID: 18244394547     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. CRAIG, W. A.: Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and Men. Clinical Infectious Disease 26: 1-12, 1998
2. KUTI, J. L.; P. DANDEKAR, C. H. NIGHTINGALE & D. P. NICOLAU: Use of monte carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J. Clin. Pharmacol. 43: 1116-1123, 2003
3. KUTI, J. L.; C. H. NIGHTINGALE & D. P. NICOLAU: Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in north America in 2002. Antimicrobial. Agents Chemotherapy. 48 7: 2464-2470, 2004
4. Chemotherapy 40 (S-1): 258-275, 1992
5. JARURATANASIRIKUL, S. & S. SRIWIRIYAJAN: Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection. J. Antimicrob. Chemother. 52: 518-521, 2003
6. Jpn. J. Antibiotics 57 (1): 70-104, 2004
7. WALKER, M. R.; D. ANDES, W. A. CRAIG, et al.: Pharmacodynamic activities of meropenem in animal infection model. ICAAC Abstr A-91, 1994
8. ARIANO, R. E.; A. NYHIEN, J. P. DONNELLY, D. S. SITAR, G. K. M. HARDING & S. A. ZELENITSKY: Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. The Annals of Pharmacotherapy 39: 32-38, 2005
9. LEROY, A.; J. P. FILLASTRE, I. ETIENNE, F. BORSA-LEBAS & G. HUMBERT: Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur. J. Clin. Pharmacol. 42 (5): 535-538, 1992
10. KUTI, J. L.; S. KOTAPATI, C. H. NIGHTINGALE, D. P. NICOLAU: Evaluation of Pharmacodynamic Target Attainment Between Healthy Subject and Patients Data Using Monte Carlo Simulation. ICAAC Abstr # A-9, 2003